Your session is about to expire
← Back to Search
Pembrolizumab for Gastric Cancer
Study Summary
This trial is testing a combination of drugs to treat gastric or gastroesophageal junction cancer that has come back or spread. The drugs are designed to boost the immune system and kill cancer cells.
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Have there been previously conducted investigations into Pembrolizumab?
"Pembrolizumab's development was kickstarted at the City of Hope Comprehensive Cancer Center in 1997, with 1330 trials now concluded. Currently, 1747 studies are ongoing; many of them taking place in Dallas, Texas."
To what extent is this medical study engaging participants?
"At this time, recruitment for the trial is closed as it was last updated on May 31st 2022. If you are searching for other studies involving adenocarcinoma and Pembrolizumab, there are a total of 2284 trials actively seeking participants and 1747 clinical studies recruiting patients with the aforementioned drug respectively."
In what cases is Pembrolizumab commonly prescribed?
"Pembrolizumab is a viable therapy for the treatment of malignant melanoma, recurrent cervical cancer and leukemia."
Are there any openings in this research initiative for those seeking participation?
"Currently, this medical trial is not actively seeking participants. Last updated on May 31st 2022, the original post was made 19th April 2019. If you are looking for alternative trials to join, there are 2,284 studies recruiting those with adenocarcinoma and 1,747 clinical trials that utilize pembrolizumab in their treatment protocol currently open to enrolment."
Share this study with friends
Copy Link
Messenger